STAT News

STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.

By STAT News

1 min read
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights